Press Releases

Date Title and Summary  
Toggle Summary Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14
BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 7, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate in a fireside chat at the BMO Capital
Toggle Summary Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 20, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017 .
Toggle Summary Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2017 .
Toggle Summary Aimmune Therapeutics to Participate in Four Investor Conferences in November
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 1, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor
Toggle Summary Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial
— Study Showed that Six Months of AR101 Treatment Could Significantly Reduce Clinical Reactivity to Peanut in Approximately 80 Percent of Subjects Enrolled — — First Peer-Reviewed Publication of Efficacy and Safety of an Industry-Sponsored Food Allergy Trial — BRISBANE, Calif.
Toggle Summary Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings
— Poster Presentations Will Discuss Global Screening Data from Aimmune’s Phase 3 PALISADE Trial and Current Approaches to Oral Immunotherapy — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 19, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for
Toggle Summary Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
— Phase 2 Clinical Trial Will Explore AR101 Treatment with Adjunctive Dupilumab in Peanut-Allergic Patients — — Trial Design Will Test Potential to Achieve Sustained Unresponsiveness to Peanut Following Treatment — — Conference Call Today at 8:30 a.m. Eastern Time / 5:30 a.m.
Toggle Summary Aimmune Therapeutics to Participate in Three Investor Conferences in September
BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will be presenting at three upcoming investor
Toggle Summary Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 9, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the 2017 Wedbush PacGrow Healthcare
Toggle Summary Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
BRISBANE, California --(BUSINESS WIRE)--Aug. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2017 .